Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% in mild to moderate Alzheimer's disease
NCT00812565Phase 2Completed
- Sponsor
- Octapharma
- Start
- Feb 2009
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human normal immunoglobulin in Alzheimer's disease (AD), sponsored by Octapharma. Started Feb 2009; status: completed.
02
Drugs
human normal immunoglobulin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00812565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00812565.